NovoCure (NVCR) Depreciation & Amortization (CF) (2014 - 2026)

NovoCure (NVCR) has reported Depreciation & Amortization (CF) for 13 consecutive years, with $4.3 million the latest figure, recorded in Q2 2026.

• Quarterly Depreciation & Amortization (CF) rose 25.06% year-over-year to $4.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $16.3 million (up 32.28% YoY) and the FY2025 annual result came in at $14.6 million, up 30.4% from the prior year.
• Depreciation & Amortization (CF) grew to $4.3 million in Q2 2026 per NVCR's latest filing, from $4.1 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for NVCR reached as high as $4.3 million in Q2 2026 and fell as low as $2.5 million in Q3 2024.
• A 5-year average of $3.1 million and a median of $2.8 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) slipped 12.31% — and 2025, when it jumped 49.02%.
• Year by year, Depreciation & Amortization (CF) stood at $2.7 million in 2022, then rose by 0.85% to $2.7 million in 2023, then grew by 13.99% to $3.1 million in 2024, then soared by 35.89% to $4.2 million in 2025, then gained by 2.11% to $4.3 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $4.3 million, $4.1 million, and $4.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.